In co-cultures with HMC3, both A172 and U87MG cells, showed enhanced Siglec-11/Fc binding capacity when compared to monocultured glioma cells (A172/HMC3: 14.07 ± 1.6 vs. 10.3 ± 1.04 monoculture; U87MG/HMC3: 13.95 ± 1.2 vs. 10.46 ± 0.9 monoculture). The gene discussed is SIGLEC11; the disease is glioma.